Investigational adjunctive treatment for major depressive disorder; clinical evidence and delivery economicsNovember 17, 2026

HLP003’s Phase 3 Benefit Gives Helus a More Concrete Development and Delivery Case

HELP

Executive Summary

APPROACH adds randomized Week 6 and Week 12 symptom-benefit evidence for adjunctive HLP003. Serious-event details, masking, replication and the economics of supervised delivery remain central to Helus’s development case. BioScore unverified; no editorial investment rating assigned.

For people whose depression remains inadequately controlled on an antidepressant, a treatment that adds meaningful symptom relief without requiring abandonment of the existing regimen would have practical value. Helus Pharma’s first pivotal HLP003 result gives that proposition a randomized Phase 3 foundation. For investors in Helus (Nasdaq: HELP), the next task is to connect that benefit to a reproducible treatment pathway, an acceptable safety profile and a fundable development plan.

HLP003 is investigational deuterated psilocin, a serotonergic psychedelic candidate. The relevant product proposition is adjunctive treatment: the study tested an addition to stable antidepressant therapy. It does not establish that patients should replace their antidepressants with HLP003, or that the candidate is ready for unsupervised use. [1,2]

What the first pivotal study adds

The November 16 company disclosure describes 222 intention-to-treat participants, 112 assigned to HLP003 and 110 to placebo. At Week 6, the primary endpoint, adjusted mean MADRS depression-score reductions were 19.5 and 11.9 points, respectively: a reported between-group difference of 7.6 points favoring HLP003 (p<0.0001). At Week 12, the key secondary endpoint, reductions were 16.9 versus 9.9 points, a 7.0-point difference (p<0.0001). The company also reported three treatment-related serious adverse events. [1]

That is an important advance beyond an uncontrolled before-and-after observation. Both groups received ongoing antidepressant treatment, while randomization provides a basis for comparing the added intervention. The placebo group’s improvement belongs in the interpretation: attributing the entire active-group reduction to the molecule would overstate what the comparison establishes.

MADRS is a clinician-rated symptom scale. A statistically persuasive average difference supports efficacy, but does not by itself establish how many additional people can return to work, maintain relationships or avoid hospitalization. Those outcomes have distinct clinical and economic importance. Nor does a group-level benefit at Week 12 identify which individual patients remained well continuously throughout follow-up.

The available result is a company topline disclosure. A peer-reviewed full report, complete protocol and statistical analysis plan were not obtained for this review. The cited release does not supply confidence intervals for the headline treatment differences. Missing-data handling, discontinuations, endpoint hierarchy and sensitivity analyses therefore remain important documents to examine, rather than gaps to fill with assumed methods. The official company directory identifies APPROACH as NCT06564818; the full registry record did not render in the retrieval used here. [1–3]

Why trial conduct matters for a psychedelic

Randomization and successful masking answer different questions. Randomization helps balance the groups at the start. If distinctive subjective effects allow participants or staff to infer allocation, expectations and subsequent interactions can still influence symptom assessments. That possibility does not establish that the observed benefit is spurious; it makes the safeguards and their measured performance part of the evidence.

FDA’s July 2026 final psychedelic-drug guidance discusses functional unblinding, independent central ratings, assessments of treatment guesses and expectations, and durability beyond 12 weeks. It is guidance for a drug class, not an FDA finding about APPROACH. For HLP003, the useful next evidence would include the actual rater procedures, masking assessments and analyses showing whether the result remains robust across relevant endpoints and assumptions. [4]

This distinction also affects competition. HLP003 would have to earn a place among existing depression treatments and other investigational approaches through its own eligible population, benefit, risks and treatment process. A favorable number from a different trial, with different background therapy or follow-up, would not establish superiority. The commercial comparator is the complete care pathway available to a patient, as well as the pharmacology.

Keep the serious events in the investment case

The three treatment-related serious adverse events in the company release must remain visible alongside efficacy. That is an event count, not a verified count of affected patients; calculating a patient incidence as three divided by 112 would be unjustified. Describing many other events as transient or mild does not resolve the significance of the serious events. [1]

The accessible primary release does not provide the individual narratives and a complete safety table needed to assess those events in detail. The official event page lists a results presentation, but its linked file could not be retrieved in this review. Secondary accounts of specific events are consequently not treated here as independently verified primary safety evidence. The unresolved questions include timing, affected-patient counts, clinical course, allocation, attribution and follow-up. [1,7]

These gaps matter to development and potential adoption. They can change eligibility, monitoring, informed consent and the resources required around treatment. It would be premature either to dismiss the events because the overall efficacy result is positive or to infer from the count alone that a favorable benefit–risk assessment is impossible.

The potential product includes a service

A treatment that needs supervised sessions has an economic constraint beyond manufacturing tablets: trained staff and treatment capacity. FDA’s class guidance describes observation by two monitors during treatment sessions and emergency support. These clinical-investigation recommendations do not establish a future HLP003 label or its eventual reimbursed delivery model. [4]

Our commercial inference is that staffing, room occupancy, preparation, discharge arrangements and repeat treatment could influence access even if drug efficacy is confirmed. Fewer administrations could be attractive to patients, but a small number of intensive visits need not be cheap or convenient. Travel, caregiver time and appointment availability also affect the fraction of eligible patients who actually start and complete treatment.

An investment model should therefore keep drug economics and treatment-site economics separate. The sponsor may receive product revenue while providers bear much of the staffing burden. A commercially viable drug price would not, on its own, prove that sites can deliver enough sessions profitably or that insurers will fund the whole pathway. No HLP003 price, treatment-site margin, revenue forecast or market-share assumption is established by the present data.

The next studies and the cash needed to reach them

Helus describes EMBRACE as the second pivotal study, with results expected in the fourth quarter of 2027, and EXTEND as evaluating longer-term safety, durability and potential redosing. These are company plans and ongoing research, not completed confirmatory evidence or approval commitments. Replication would address a different uncertainty from longer observation: whether the randomized benefit can be reproduced, and how treatment works over time, respectively. [1,5]

The September 30 unaudited statements report $171.071 million of cash and $72.373 million of operating cash use over six months. The same period’s $150.910 million net loss included $76.535 million of noncash share-based compensation. Net loss and cash burn are therefore materially different measures in this case. [6]

Those figures frame financing exposure, but they are not a guaranteed runway. Future trial activity, working capital, other programs and commercialization preparation may change spending. Cash is also committed to running the business, rather than being an amount automatically distributable to shareholders. A stronger clinical result may improve financing options; it does not establish the terms, amount or absence of future dilution.

What would change the judgment

APPROACH makes the HLP003 development thesis more concrete: the candidate has a reported randomized adjunctive symptom benefit that extends to a prespecified 12-week assessment. The opportunity now rests on turning that signal into a reliable and deliverable treatment proposition.

The most consequential next materials are the full efficacy and safety analyses, serious-event narratives and masking assessments; then the second pivotal result and longer-term retreatment evidence. Alongside them, investors need a realistic account of treatment capacity, reimbursement and capital requirements. Favorable answers could strengthen the connection between clinical benefit and commercial value. Unfavorable answers could narrow that opportunity without erasing the benefit already observed in this study.

No editorial investment rating or price target is assigned. This analysis separates company-reported findings, FDA’s general guidance and our commercial inferences; it does not anticipate an FDA decision.

Sources and evidence status

[1] Helus, APPROACH topline results, November 16, 2026; company disclosure, not a peer-reviewed full report https://ir.helus.com/node/11511/pdf

[2] Helus, official clinical-trials directory; APPROACH registration link https://www.helus.com/clinical-trials/

[3] APPROACH registration, NCT06564818; full record/protocol was not retrieved in this review https://clinicaltrials.gov/study/NCT06564818

[4] FDA, Psychedelic Drugs: Considerations for Clinical Investigations, final guidance, July 2026; class guidance, not an HLP003 decision https://www.fda.gov/media/169694/download

[5] Helus, fiscal Q2 2027 financial and program update, November 16, 2026 https://ir.helus.com/news-releases/news-release-details/helus-pharma-reports-second-quarter-fiscal-2027-financial

[6] Helus, unaudited financial statements, three and six months ended September 30, 2026; SEC filing, amounts in thousands of US dollars https://www.sec.gov/Archives/edgar/data/1833141/000183314126000100/helus-financialstatementsx.htm

[7] Helus, official November 16 results event and presentation listing; presentation download could not be retrieved in this review https://ir.helus.com/events-presentations

BioScore

4.4/10
Cautious